Usefulness of specific OA biomarkers, Coll2-1 and Coll2-1NO 2, in the anterior cruciate ligament OA canine model

Osteoarthritis and Cartilage

Volumn 20, Issue 7, 2012, Pages 787-790

  Henrotin, Y ^a   Martel Pelletier, J ^b   Msika, P ^c   Guillou, G B ^c   Deberg, M ^d  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b NOTRE DAME HOSPITAL   (Canada)

^c Expanscience   (France)

^d Artialis SA   (Belgium)

Author keywords

Biomarkers; Cartilage; Experimental OA

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN TYPE 2; COLLAGEN TYPE 2 1; COLLAGEN TYPE 2 1 NITRIC OXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR CRUCIATE LIGAMENT; ARTICLE; BLOOD SAMPLING; CARTILAGE; DOG; HISTOLOGY; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANIMALS; ANTERIOR CRUCIATE LIGAMENT; ARTHRITIS, EXPERIMENTAL; BIOLOGICAL MARKERS; CARTILAGE, ARTICULAR; COLLAGEN TYPE II; DISEASE PROGRESSION; DOGS; OSTEOARTHRITIS; PEPTIDE FRAGMENTS;

EID: 84862115251     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2012.03.016     Document Type: Article

References (16)

1. Kraus V.B., Burnett B., Coindreau J., Cottrell S., Eyre D., Gendreau M., et al. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage 2011.
2. Henrotin Y., Addison S., Kraus V., Deberg M. Type II collagen markers in osteoarthritis: what do they indicate?. Curr Opin Rheumatol 2007, 19:444-450.
3. Deberg M., Labasse A., Christgau S., Cloos P., Bang Henriksen D., Chapelle J.P., et al. New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2005, 13:258-265.
4. Deberg M.A., Labasse A.H., Collette J., Seidel L., Reginster J.Y., Henrotin Y.E. One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression. Osteoarthritis Cartilage 2005, 13:1059-1065.
5. Lejeune J.P., Serteyn D., Gangl M., Schneider N., Deby-Dupont G., Deberg M., et al. Plasma concentrations of a type II collagen-derived peptide and its nitrated form in growing Ardenner sound horses and in horses suffering from juvenile digital degenerative osteoarthropathy. Vet Res Commun 2007, 31:591-601.
6. Gangl M., Serteyn D., Lejeune J.P., Schneider N., Grulke S., Peters F., et al. A type II-collagen derived peptide and its nitrated form as new markers of inflammation and cartilage degradation in equine osteochondral lesions. Res Vet Sci 2007, 82:68-75.
7. Huebner J.L., Williams J.M., Deberg M., Henrotin Y., Kraus V.B. Collagen fibril disruption occurs early in primary guinea pig knee osteoarthritis. Osteoarthritis Cartilage 2010, 18:397-405.
8. Ameye L.G., Deberg M., Oliveira M., Labasse A., Aeschlimann J.M., Henrotin Y. The chemical biomarkers C2C, Coll2-1, and Coll2-1NO2 provide complementary information on type II collagen catabolism in healthy and osteoarthritic mice. Arthritis Rheum 2007, 56:3336-3346.
9. Deberg M., Dubuc J.E., Labasse A., Sanchez C., Quettier E., Bosseloir A., et al. One-year follow-up of Coll2-1, Coll2-1NO2 and myeloperoxidase serum levels in osteoarthritis patients after hip or knee replacement. Ann Rheum Dis 2008, 67:168-174.
10. Boileau C., Martel-Pelletier J., Caron C., Cheng S., Msika P., Guillou G.B., et al. Protective effects of total fraction of avocado/soybean unsaponifiables (ASU) on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and MMP-13. Arthritis Res Ther 2009, 11:R41. 10.1186/ar2649.
11. Fernandes J.C., Martel-Pelletier J., Otterness I.G., Lopez-Anaya A., Mineau F., Tardif G., et al. Effects of tenidap on canine experimental osteoarthritis. I. Morphologic and metalloprotease analysis. Arthritis Rheum 1995, 38:1290-1303.
12. Sakakibara Y., Miura T., Iwata H., Kikuchi T., Yamaguchi T., Yoshimi T., et al. Effect of high-molecular-weight sodium hyaluronate on immobilized rabbit knee. Clin Orthop 1994, 299:282-292.
13. Mobasheri A., Henrotin Y. Identification, validation and qualification of biomarkers for osteoarthritis in humans and companion animals: mission for the next decade. Vet J 2010, 185:95-97.
14. Henrotin Y., Conrozier T., Deberg M., Walliser-Lohse A., Richette P., Mulleman D., et al. Early decrease of serum biomarkers of the type II collagen degradation (Coll2-1) and joint inflammation (Coll2-1 NO2) by hyaluronic acid intra-articular injections in patients with knee osteoarthritis. Ann Rheum Dis 2011, 70:395.
15. Pelletier J.P., Boileau C., Boily M., Brunet J., Mineau F., Geng C., et al. The protective effect of Licofelone on experimental osteoarthritis is correlated with the downregulation of the expression and the synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K, and aggrecanases. Arthritis Res Ther 2005, 7:R1091-R1102.
16. Boileau C., Martel-Pelletier J., Brunet J., Tardif G., Schrier D., Flory C., et al. Oral treatment with PD-0200347, an alpha2delta ligand, reduces the development of experimental osteoarthritis by inhibiting metalloproteinases and inducible nitric oxide synthase gene expression and synthesis in cartilage chondrocytes. Arthritis Rheum 2005, 52:488-500.